(provided by the applicant): The UCSD CD4 Collaborative Clinical Trials Unit (CTU) will bring together six dynamic and diverse Clinical Research Sites (CRSs) that are well prepared to respond to the research priorities of the NIAID HIV/AIDS clinical research networks. Our CTU brings together the scientific expertise and experience required to conduct a broad variety of complex clinical trials in adults, adolescents, children and pregnant women in the areas of HIV therapeutic interventions aimed at cure, functional cure and eradication of HIV;new and novel antiretroviral drug development;HIV-related co-infections and comorbidities, including opportunistic infections and other end organ diseases;treatment and prevention of tuberculosis (TB) in HIV co-infected and TB mono-infected individuals;treatment and cure of viral hepatitis in co-infected and mono-infected individuals;biomedical and behavioral interventions to reduce or prevent HIV transmission (including pre-exposure prophylaxis, post-exposure prophylaxis and vaccine prevention strategies) in high risk populations, including pregnant women;and in the pathogenesis of HIV disease, including viral persistence, latent reservoirs, viral and vaccine immunology, and vaccine development. Through our CD4 Collaborative CTU we will address the following specific aims (briefly summarized here):
Specific Aim 1 (Innovative Science Infrastructure): Provide scientific expertise and efficient, flexible infrastructure to develop new strategies to improve the prevention and treatment of HIV infection within the context of the following NIAID Clinical Research Networks on: a) Therapeutics for HIV/AIDS and HIV associated Infections in Adults;b) HIV/AIDS and HIV-associated Infections in Pediatric and Maternal Populations;c) Integrated Strategies to Prevent HIV Infection;d) Vaccines to Prevent HIV Infection.
Specific Aim 2 (Effective Scientific Leadership): Provide excellent, effective leadership in administrative coordination and scientific participation within the CTU, across the CRSs, within communities served by the CTU, and across the clinical research networks in which our CTU will participate.
Specific Aim 3 (Effective Fiscal Management and Performance): Effectively manage all financial and infrastructure resources, and oversee, evaluate and assure exemplary performance of all components.
Specific Aim 4 (Community Engagement): Engage and partner with affected communities to shape network scientific agendas and to recruit, enroll and retain ideal research trial participant in network studies.

Public Health Relevance

The UCSD CD4 Collaborative Clinical Trials Unit (CTU) brings together six dynamic Clinical Research Sites in the U.S., sub-Saharan Africa, and India, with a proven track record of significant research into the pathogenesis and treatment of HIV and its complications. Our proposed CTU has the expertise, experience, infrastructure, and access to racially and ethnically diverse adult, adolescent and pediatric patient populations to make valuable contributions to the research priorities of the NIAID clinical research networks.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
2UM1AI069432-08
Application #
8609627
Study Section
Special Emphasis Panel (ZAI1-DR-A (S1))
Program Officer
Adedeji, Bola
Project Start
2007-02-01
Project End
2020-11-30
Budget Start
2013-12-10
Budget End
2014-11-30
Support Year
8
Fiscal Year
2014
Total Cost
$4,294,438
Indirect Cost
$374,476
Name
University of California San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Chaillon, Antoine; Gianella, Sara; Wertheim, Joel O et al. (2014) HIV migration between blood and cerebrospinal fluid or semen over time. J Infect Dis 209:1642-52
Touzard Romo, F; Smeaton, L M; Campbell, T B et al. (2014) Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175). HIV Clin Trials 15:246-60
Sulkowski, Mark S; Kang, Minhee; Matining, Roy et al. (2014) Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study. J Infect Dis 209:658-67
Hatano, Hiroyu; Bacchetti, Peter; Hsue, Priscilla Y et al. (2014) Reply to Karch et al. J Infect Dis 210:159-60
Jacobson, Jeffrey M; Wang, Hongying; Bordi, Rebeka et al. (2014) A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy. J Acquir Immune Defic Syndr 66:399-406
Wallis, Carole L; Aga, Evgenia; Ribaudo, Heather et al. (2014) Drug susceptibility and resistance mutations after first-line failure in resource limited settings. Clin Infect Dis 59:706-15
Krown, Susan E; Borok, Margaret Z; Campbell, Thomas B et al. (2014) Stage-stratified approach to AIDS-related Kaposi's sarcoma: implications for resource-limited environments. J Clin Oncol 32:2512-3
King, Helen L; Keller, Samuel B; Giancola, Michael A et al. (2014) Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study). AIDS Behav 18:1722-5
Gianella, Sara; Morris, Sheldon R; Tatro, Erick et al. (2014) Virologic correlates of anti-CMV IgG levels in HIV-1-infected men. J Infect Dis 209:452-6
Little, Susan J; Kosakovsky Pond, Sergei L; Anderson, Christy M et al. (2014) Using HIV networks to inform real time prevention interventions. PLoS One 9:e98443

Showing the most recent 10 out of 53 publications